Plantar Fasciitis Market Size, Share and Global Trend By Treatment (Medication Therapy, Orthotics, Radiation Therapy, Shock Wave Therapy, Surgery, Others), By End User (Hospitals, Ambulatory Surgery Centers, Specialty Clinics, Others), and Regional Forecast, 2024-2032

Plantar fasciitis is the major cause of heel pain. The plantar fascia is a tissue that connects the heel to the toes and provides support to the muscle and arch of the foot. Plantar fasciitis is caused by the damage or inflammation of the plantar fascia. Plantar fasciitis is more prevalent in the sportsperson and over-weight people and is the most common among the population of 40-60 years. According to the National Center for Health Statistics (NCHS) report, it is estimated that globally one million population suffers from plantar fasciitis every year.

Anti-inflammatory drugs, shock wave therapy, and orthotic insoles are some of the available options for mitigating and reducing the pain caused during planar fasciitis. Growing obese population globally has led to the rising demand for effective treatment options for plantar fasciitis. For instance, in 2016 according to world health organization (WHO), it was estimated that 650 million adults were suffering from obesity and is expected to rise in the future which is likely to fuel the growth in the market of plantar fasciitis during the projected period.

Increasing prevalence of obesity and growing demand for minimally-invasive treatment methods to treat plantar fasciitis are the major factors likely to drive the plantar fasciitis market during the forecast period. In addition, consistence advancement in pharmaceutical and medical fields is also to fuel the growth of plantar fasciitis market during the forecast period.

However, the high cost associated with the treatment of plantar fasciitis is anticipated to hamper the growth in plantar fasciitis market during the projected period.

Key Players Covered

Some of the major companies that are present in the global plantar fasciitis market are Superfeet Worldwide Inc., Sanofi, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer Inc., Allergan plc., Bristol-Myers Squibb Company, Bayer AG, Bauerfeind AG, Ottobock Holding GmbH, F. Hoffmann-La Roche Ltd., among others.

SEGMENTATION

Among end users, hospitals and ambulatory surgery centers are anticipated to hold the largest market share owing to the favourable reimbursement policies and growing emergency visits of patients with plantar fasciitis.

Key Insights

• Epidemiology analysis of Plantar Fasciitis


• Overview of Advancement in Therapy for Plantar Fasciitis


• Pricing Analysis for Key Products/Therapies


• The Regulatory Scenario for Key Countries/Regions


• Key Industry Developments – Mergers, Acquisitions, and Partnerships

Regional Analysis

Geographically, the global Plantar fasciitis can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to have a major portion in the global plantar fasciitis market during the forecast period due to the growing obese population in the U.S. For instance, in 2016, according to OECD Health Statistics, it was estimated that the obesity rate among adult population was 40% in united states. In addition, growing investments in the development of oral medications and effective therapy for the treatment of plantar fasciitis by many research organizations and pharmaceutical company are likely to boost the plantar fasciitis market in North America during the forecast period. In the Asia Pacific region, the plantar fasciitis market is likely to grow at a significant rate during the forecast period owing to increase in the geriatric patient population, growing adoption of a sedentary lifestyle, and an increase in the demand for cost-effective treatment for plantar fasciitis.

Key Industry Developments 

• In September 2018, FDA reduced the follow-up requirement from two years to one year for a Phase IIb study of injectable AmnioFix for the treatment of plantar fasciitis.
• In February 2017, BioElectronics Corporation received FDA approval of ActiPatch as drug-free pain therapy for plantar fasciitis and osteoarthritis which was highly efficient in treatment and demonstrated no harmful effects in patients.